News related to Acular (Ketorolac Ophthalmic) and/or conditions it is approved for
Age-related macular degeneration occurs much earlier than previously assumed
Source: Eye Health / Blindness News From Medical News Today [2014.07.22]
It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries.
Allergan receives FDA approval for Ozurdex® treatment option for use in certain patients with diabetic macular edema
Source: Eye Health / Blindness News From Medical News Today [2014.07.02]
Allergan, Inc., has announced that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® as a new treatment option for diabetic macular edema (DME) in adult patients who have an...
Source: MedicineNet Eyeglasses, Sunglasses, and Magnifiers Specialty [2014.01.23]
Title: Macular Degeneration
Category: Diseases and Conditions
Created: 7/23/1999 6:05:00 PM
Last Editorial Review: 1/23/2014 12:00:00 AM
Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.
'Miniature Telescope' for Eye Approved for Macular Degeneration
Source: MedicineNet Macular Degeneration (Age-Related Type) Specialty [2010.07.07]
Title: 'Miniature Telescope' for Eye Approved for Macular Degeneration
Category: Health News
Created: 7/6/2010 2:10:00 PM
Last Editorial Review: 7/7/2010
EU Panel Endorses Use of 2 Diabetes-Related Products
Source: Medscape Medical News Headlines [2014.07.25]
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing of Xultophy to treat type 2 diabetes, and a new diabetic macular edema indication for Ozurdex.
Rehab for age-related loss of vision cuts depression risk in half
Source: Eye Health / Blindness News From Medical News Today [2014.07.10]
Research finds that a technique called behavioral activation leads to a 50% decrease in the chances of people with age-related macular degeneration developing clinical depression.
Ruboxistaurin (RBX) may reduce risk of vision loss in diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
Phase III trial demonstrates ruboxistaurin (RBX) may reduce the risk of vision loss especially in diabetic macular edema.